COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Study Type
OBSERVATIONAL
Enrollment
183
Dosage of MR-pro-ADM
Hospital of Arras
Arras, France
Hospital of Boulogne/mer
Boulogne-sur-Mer, France
Hospital of DOUAI
Douai, France
Hospital of Dunkerque
Dunkirk, France
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
Association or correlation between MR-ProADM at day 1 and day 3 and the onset of visceral failures extra respiratory in reanimation.
Time frame: comparison to day 1 and day 3
mortality at day 28 and day 90.
mortality at day 28 and day 90.
Time frame: admission until day 90
Association between MR-ProADM and mortality at day 28.
Association between MR-ProADM and mortality at day 28.
Time frame: admission until day 28
Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.
Association or correlation between patient factor or treatment, and the onset or aggravation of visceral failures (day 3 and day 10), evolution until day 28.
Time frame: admission until day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Dr Schaffner
Lens, France
Hospital of Roubaix
Roubaix, France
Hospital of Tourcoing
Tourcoing, France
Hospitalier of Valenciennes
Valenciennes, France